US Expansion Agno Pharma is expanding its U.S. footprint with FDA-inspected GMP facilities and sterile injectable capabilities, offering near-shore, reliable manufacturing for North American pharma and biotech companies seeking regulatory confidence and smoother technology transfer.

API Capabilities Acquiring Actylis's CDMO assets enhances US cGMP API development and manufacturing, enabling opportunities to supply high-quality APIs and complex synthesis programs to regulated customers.

Formulation Alliances Partnership with Particlesciences strengthens formulation development and drug product capabilities, enabling joint opportunities to support early-stage and commercial programs with optimized formulations and ready-for-fill-finish solutions.

Advanced Delivery Collaboration with SiCare Bio signals capacity to scale advanced drug-delivery platforms, creating sales opportunities with biotech and pharma clients pursuing novel modalities, targeted delivery, or controlled-release products.

Global Growth Aggressive acquisitions and partnerships, including the Lubrizol Particle Sciences deal, position Agno as a global CDMO with end-to-end capabilities across development, cGMP manufacturing, and sterile injectable production, appealing to multinational and generic manufacturers seeking a single, scalable partner.